Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Published online February 1, 2023.
Article Versions
- You are currently viewing a Latest version of this article (February 1, 2023 - 04:00).
- latest version (February 15, 2023 - 04:00).
- View the most recent version of this article
Copyright & Usage
© 2023 The Journal of Rheumatology
Author Information
- Gabriela L. Maica,
- Christine Iannaccone,
- Vivi Feathers,
- Michelle Frits,
- Vivian Bykerk,
- Clifton O. Bingham III,
- Michael Weinblatt and
- Nancy A. Shadick
- Division of Rheumatology, Inflammation & Immunity, Brigham & Women's Hospital, Boston, MA 02115, United States of America.
- Division of Rheumatology, Inflammation & Immunity, Brigham & Women's Hospital, Boston, MA 02115, United States of America.
- Division of Rheumatology, Inflammation & Immunity, Brigham & Women's Hospital, Boston, MA 02115, United States of America.
- Division of Rheumatology, Inflammation & Immunity, Brigham & Women's Hospital, Boston, MA 02115, United States of America.
- Division of Rheumatology, Hospital for Special Surgery, New York, NY 10021, United States of America.
- Division of Rheumatology and Allergy and Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore MD 21205, United States of America.
- Division of Rheumatology, Inflammation & Immunity, Brigham & Women's Hospital, Boston, MA 02115, United States of America.
- Division of Rheumatology, Inflammation & Immunity, Brigham & Women's Hospital, Boston, MA 02115, United States of America.
- Research reported in this publication was supported by Mallinckrodt Pharmaceuticals. The funders had no role in study design, data collection, analysis, decision to publish, or preparation of the manuscript.
Gabriela L Maica has no conflicts of interest to report. Christine Iannaccone has no conflicts of interest to report. Michelle Frits has no conflicts of interest to report. Dr. Bykerk receives <10K consultancies from Amgen, Pfizer, BMS, and UCB. Dr. Bingham is an executive committee member for the Outcome Measures in Rheumatology (OMERACT) group which receives arms-length funding from more than 23 pharmaceutical and research organizations. He receives no remuneration for these activities. Dr. Weinblatt receives <10K consultancies from AbbVie, Amgen, Aclaris, Bayer, Briston Myers Squibb, Novartis, Roche, GlaxoSmithKline, Johnson and Johnson, Eli Lilly, Pfizer, Kyverna, Kiniksa, RPharma, and Gilead. Dr. Weinblatt reports >10K consultancies from CorEvitas, ChemoEvitas. He receives a research grant which is sponsored by Amgen, Bristol- Myers Squibb, Eli Lilly and Sanofi. Dr. Shadick receives <10K consultancies from Bristol-Myers Squibb. Dr. Shadick receives a research grant from Mallinckrodt Pharmaceuticals. Dr. Shadick receives a research grant from BWH which is sponsored by Amgen, Bristol-Myers Squibb, Eli Lilly and Sanofi.
Corresponding Author: Nancy A Shadick, MD, MPH Division of Rheumatology, Immunology & Allergy, Brigham & Women's Hospital, Boston, MA 02115, United States of America Email Address: gmaica@bwh.harvard.edu